<DOC>
	<DOCNO>NCT01668498</DOCNO>
	<brief_summary>80 - 90 % patient treat anti-EGFR antibody ( panitumumab cetuximab ) experience skin toxicity , mostly acne like skin rash . A standardized treatment skin rash neither establish standard arm clinical trial guideline treatment skin toxicity clinical practice . While improvement QoL demonstrate panitumumab cetuximab comparison best supportive care data basis patient relate outcomes regard skin toxicity derive randomize trial still small . Recent survey among German oncologist reveal physician reluctant use oral antibiotic preemptive treatment . Only 19 110 oncologist state think use preemptive treatment patient acne-like skin rash . Thus , present trial two main question address : ( ) Can preemptive treatment oral doxycycline replace sequential skin treatment strategy ( i.e . local treatment erythromycin follow doxycycline case inefficacy = development acne ) without compromise treatment efficacy skin toxicity treatment ? ( ii ) Comparison general skin relate QoL treatment arm .</brief_summary>
	<brief_title>Comparison Two Preemptive Treatment Strategies Panitumumab Mediated Skin Toxicity Assessment QoL Patient With Ras-wt Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients wildtype RAS ( KRAS NRAS ) status metastatic colorectal cancer treatment panitumumab accord label RAS wildtype test KRAS exon 2 ( codon 12/13 ) KRAS exon 3 ( codon 59/61 ) KRAS exon 4 ( codon 117/146 ) NRAS exon 2 ( codon 12/13 ) NRAS exon 3 ( codon 59/61 ) NRAS exon 4 ( codon 117/146 ) 2. treatment preemptive study medication shall begin day treatment start panitumumab 3 . Willingness cope biweekly quality life questionnaires 4 . Written Informed consent 5 . Aged least 18 year 6 . ECOG Performance Status 02 7 . Life expectancy least 12 week 8 . Adequate haematological , hepatic , renal metabolic function parameter : Leukocytes &gt; 3000/mm³ ANC ≥ 1500/mm³ Platelets ≥ 100,000/mm³ Haemoglobin &gt; 9 g/dl Serum creatinine ≤ 1.5 x ULN Bilirubin ≤ 1.5 x ULN GOTGPT ≤ 2.5 x ULN ( case liver metastasis GOT / GPT ≤ 5 x ULN ) AP ≤ 5 x ULN Magnesium , Calcium potassium within normal range ( may substitute study entry ) Exclusion criterion : 1 . Subject pregnant breast feeding , plan become pregnant within 6 month end treatment . 2 . Subject ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment ( adequate : oral contraceptive , intrauterine device barrier method conjunction spermicidal jelly ) . 3 . Serious concurrent diseases 4 . Ontreatment participation clinical study period 30 day prior inclusion 5 . Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrolment . 6 . History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . 7 . History HIV infection . 8 . Other previous concurrent malignancy ( ≤ 5 year prior enrolment study ) except nonmelanoma skin cancer cervical carcinoma FIGO stage 0 1 patient continuously diseasefree 9 . Known allergic reaction panitumumab , doxycycline erythromycin 10 . Previous treatment anticancer agent direct EGFR ( e.g . cetuximab , panitumumab , erlotinib , gefitinib , lapatinib ) 11 . Skin rash exist due reason panitumumab treatment 12 . Other dermatologic disease may interfere correct grade panitumumab induce skin rash 13 . Parallel treatment antitumor agent panitumumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Can preemptive treatment panitumumab mediate skin</keyword>
	<keyword>toxicity oral doxycycline replace local treatment erythromycin ?</keyword>
	<keyword>Panitumumab</keyword>
</DOC>